


Claims:

1. Pyrazolopyrimidinethione derivatives having the structure of formula I :




Wherein: R₁, R₂, and R₃ are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₅ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkylol having 1-6 carbon atoms.

2. The pyrazolopyrimidinethione derivatives according to claim 1, characterized in that: said derivatives have the structure of formula II ,



Wherein, R₁, R₂, R₃, R₄, and R₅ dependently are alkyl having 1-6 carbon atoms.

3. The pyrazolopyrimidinethione derivatives according to claim 1, wherein said pyrazolopyrimidinethione derivatives are:

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-

7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-propoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione; or

5-[2-propoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione.


10 4. The salts of pyrazolopyrimidinethione derivatives according to any one of claims 1-3, characterized in that: said salts are salts of organic acids or inorganic acids.

5. The salts according to claim 4, characterized in that: said salts of organic acids are citrate, fumarate, oxalate, malate, lactate, camphorsulfonate, p-toluenesulfonate, or methanesulfonate; said salts of inorganic acids are salts of haloid acid, sulfate, phosphate, or nitrate.


15 6. The solvates of the compounds according to any one of claims 1-5, characterized in that: the solvents are water, ethanol, or methanol.

7. A method for preparing the pyrazolopyrimidinethione derivatives of claim 1, comprising reacting the compound of formula III with the compound of formula IV to give said pyrazolopyrimidinethione derivatives;

20



(III)



(IV)

Wherein: in the compounds of formulas III and IV, R₁, R₂, and R₃ are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

25

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;


R₃ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyloyl having 1-6 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyloyl having 1-6 carbon atoms; and


5 Y is Cl, F, Br, or I.

8. The method according to claim 7, characterized in that: the solvents used in the reaction are chloroform, tetrahydrofuran, dioxane, ethanol, 1,2-dimethoxyethane, xylene, toluene, dimethyl sulfoxide, or triethylamine.


9. A method for preparing the pyrazolopyrimidinethione derivates of claim 1, comprising firstly
10 reacting the compound of formula V with the compound of formula IV to give the compound of formula VI, and then sulfurizing said compound of formula VI to give said pyrazolopyrimidinethione derivatives;



(V)



(IV)



(VI)

Wherein: in the compounds of formula IV, V, and VI, R₁, R₂, and R₃ are same or different, and
15 independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

20 R₅ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyloyl having 1-6 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyloyl having 1-6 carbon atoms; and

Y is Cl, F, Br, or I.

25 10. The method according to claim 9, characterized in that: the solvent for sulfurization reaction is tetrahydrofuran, dioxane, 1,2-dimethoxyethane, ethanol, xylene, toluene, dimethyl

sulfoxide, or triethylamine.

11. The method according to claim 10, characterized in that: the sulfurating reagent for said
sulfurization is phosphorus pentasulfide or
2,4-Bis(p-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide, and derivatives thereof, and the
5 temperature is -20-200°C.

12. A method for preparing the salts of pyrazolopyrimidinethione derivatives of claim 4,
comprising reacting said pyrazolopyrimidinethione derivatives of claim 1 with the pharmaceutically
acceptable acids to give said salts.

13. A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or
10 3 as the active ingredient, for preventing and/or treating impotence.

14. A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or
3 as the active ingredient, for preventing and/or treating frigidity.

15. A pharmaceutical comprising salts of the pyrazolopyrimidinethione derivatives of claim 4
or 5 as the active ingredient, for preventing and/or treating impotence.

16. A pharmaceutical comprising salts of the pyrazolopyrimidinethione derivatives of claim 4
or 5 as the active ingredient, for preventing and/or treating frigidity.

17. A pharmaceutical comprising solvates of the pyrazolopyrimidinethione derivatives of claim
6 as the active ingredient, for preventing and/or treating impotence.

18. A pharmaceutical comprising solvates of the pyrazolopyrimidinethione derivatives of claim
20 6 as the active ingredient, for preventing and/or treating frigidity.

19. A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or
3, or salts or solvates thereof, as the active ingredient for preventing and/or treating impotence and
frigidity.

20. The pharmaceutical according to claim 19, characterized in that: said pharmaceutical
25 further comprises a pharmaceutically acceptable diluent or carrier.